Clinical Trials Logo

Dyslipidemias clinical trials

View clinical trials related to Dyslipidemias.

Filter by:

NCT ID: NCT01658137 Active, not recruiting - Clinical trials for Cardiovascular Diseases

Diet Intervention and GEnetic STudy (DIGEST-Pilot)

DIGEST
Start date: July 2012
Phase: N/A
Study type: Interventional

Genetic factors contribute to risk factors for cardiovascular disease, such as blood lipids, blood pressure, obesity, diabetes, and may also influence dietary choices, physical activity, and responses to stress. The most robust genetic variant associated with myocardial infarction (MI) is the 9p21 variant, which may raise the risk of MI by up to 40% in those who carry 2 copies of the gene. The investigators recently found that among those who carry the 9p21 variant, the risk of MI may be "turned off" if individuals eat a diet high in fruits and vegetables. The investigators seek to determine how a "prudent" or "anti-inflammatory" diet interacts with the 9p21 risk allele to alter the risk of MI.

NCT ID: NCT01651065 Completed - Obesity Clinical Trials

Micro-Clinic Obesity and Metabolic Risk Prevention Program

Start date: June 2011
Phase: N/A
Study type: Interventional

The purpose of this randomized trial is to study the efficacy of a novel social propagation intervention which integrates social network induction with health education for weight and metabolic control among patients with type 2 diabetes, BMI of 25-30+, and cardiovascular disease. The intervention takes place in the form of a community health program, where participants who enroll in this program will be asked if they would like to take part in the study to evaluate its efficacy. Thus, the investigators will study the efficacy of social networks in propagating changes in lifestyle factors for diabetes and chronic disease management

NCT ID: NCT01632358 Completed - Dyslipidaemia Clinical Trials

Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients

Start date: June 2012
Phase: Phase 1
Study type: Interventional

The study will assess the safety, tolerability and pharmacokinetics of TAP311 in patients with dyslipidemia.

NCT ID: NCT01630980 Completed - Obesity Clinical Trials

Meta-analyses of the Effect of Tree Nuts on Glycemic Control and Features of the Metabolic Syndrome

Start date: May 2012
Phase: N/A
Study type: Observational

Tree nuts (almonds, Brazil nuts, cashews, hazelnuts, macadamia nuts, pecans, pine nuts, pistachios and walnuts) are an important source of unsaturated fatty acids, vegetable protein, and fibre, as well as minerals, vitamins, and phytonutrients. Although heart disease risk reduction claims for nuts have been permitted in the U.S. and general dietary guidelines and recommendations from heart associations recommend the consumption of nuts for heart protection, diabetes associations have not addressed nuts in their most recent recommendations. This omission is despite heart disease being a major cause of death in diabetes. There remains insufficient information on the usefulness of these foods in diabetes. To improve evidence-based guidance for tree nut recommendations, the investigators propose to conduct a systematic review of the effect of tree nuts on diabetes control and features of the metabolic syndrome. The systematic review process allows the combining of the results from many small studies in order to arrive at a pooled estimate, similar to a weighted average, of the true effect. The investigators will be able to explore whether eating tree nuts has different effects between men and women, in different age groups and background disease states, and whether or not the effect of tree nuts depends on the dose and background diet. The findings of this proposed knowledge synthesis will help improve the health of Canadians through informing diabetes association recommendations and heart association recommendations where they relate to diabetes.

NCT ID: NCT01613729 Enrolling by invitation - Dyslipidemia Clinical Trials

Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin

Cor16
Start date: July 2012
Phase: Phase 4
Study type: Interventional

The primary objective of the study is to compare the efficacy of Rosuvastatin 5 mg once daily with Rosuvastatin 10 mg once daily by assessment of the number of patients with hypercholesterolemia reaching the LDL-C target goal of <100 mg/dL after 12 weeks of therapy.

NCT ID: NCT01610661 Completed - Dyslipidemia Clinical Trials

Dietary Carbohydrate Type and Cardiovascular Disease (CVD) Risk Indicators

Start date: January 2012
Phase: N/A
Study type: Interventional

The aim of this study is to determine the effect of habituation to diets with different types of carbohydrate (simple-carb, refined-carb, unrefined-carb) on selected Cardiovascular Disease (CVD) risk indicators.

NCT ID: NCT01608620 Active, not recruiting - Obesity Clinical Trials

Meta-analyses of Fructose-containing Sugars and Incident Cardiometabolic Disease

Start date: May 2012
Phase: N/A
Study type: Observational

Since uncontrolled observational studies first linked fructose to the epidemic of obesity almost a decade ago, it has become a focus of intense concern regarding its role in the obesity epidemic and increasing burden of cardiometabolic disease. Despite the uncertainties in the evidence, international health organizations have cautioned against moderate to high intakes fructose-containing sugars, especially those from sugar sweetened beverages (SSBs). To improve the evidence on which nutrition recommendations are based, the investigators propose to study of the role of fructose-containing sugars in the development of overweight/obesity, diabetes, hypertension, gout, and cardiovascular disease, by undertaking a series of systematic syntheses of the available prospective cohort studies. Prospective cohort studies have the advantage of relating "real world" intakes of sugars to clinically meaningful disease endpoints over long durations of follow-up. The findings generated by this proposed knowledge synthesis will help improve the health of consumers through informing recommendations for the general public, as well as those at risk of diabetes and cardiovascular disease.

NCT ID: NCT01604681 Recruiting - Hypertension Clinical Trials

Supplementation With Flaxseed Oil in the State of Rio de Janeiro

Start date: January 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effect of supplementation with flaxseed oil combined with a nutritional counseling in reducing cardiovascular risk factors in homocysteine , biomarkers of inflammation, oxidative stress, improving quality of life and cognitive decline in hypertensive and dyslipidemic genotyped for the C677T and A1298C polymorphisms of methylenetetrahydrofolate reductase gene.

NCT ID: NCT01603758 Completed - Clinical trials for Cardiovascular Disease

Physiological Study of Human Cholesterol Metabolism and Excretion

Start date: January 2014
Phase: Phase 1
Study type: Interventional

The underlying hypothesis is that whole body cholesterol - including cholesterol present in tissues that cannot be measured by standard blood tests - is related to heart disease risk. Endogenous cholesterol will be labeled with an intravenous infusion of one type of cholesterol tracer and dietary cholesterol will be labeled with another. These tracers will be used to measure how fast cholesterol is synthesized and excreted using mass spectrometry to distinguish the tracers. Data will be related to circulating biomarkers (blood tests) and to the thickness of the lining of the carotid artery. The effect of the drug ezetimibe on these processes will also be determined. Successful completion of this study will give us more knowledge about cholesterol metabolism that may be useful in designing new drugs and treatments for patients with heart disease, especially those that are already receiving maximum amounts of current medications.

NCT ID: NCT01600690 Completed - Clinical trials for Type 2 Diabetes Mellitus

Effects of 5-day Statin Withdrawal on Endothelial Progenitor Cells and Inflammatory Markers in Type 2 Diabetic Patients

SStatin-EPC
Start date: May 2012
Phase: Phase 4
Study type: Interventional

Statins are commonly prescribed to lower cardiovascular risk in primary and secondary prevention. Despite their well known efficacy, statin withdrawal is a common event. Even a short term statin withdrawal can have dramatic consequences on atherosclerotic plaque stability, owing to a rebound in cholesterol levels and inflammation. The effects of a short term statin withdrawal on endothelial progenitor cells (EPC) and monocyte/macrophage polarization is unknown. In this study, the investigators will explore the effects of a 5-day statin withdrawal on EPC and monocyte/macrophage polarization, together with other inflammatory biomarkers in type 2 diabetic patients. The investigators hypothesize that statin withdrawal determines a reduction in EPC levels and an inflammatory cell polarization. Patients will be randomized to continue their habitual statin regimen or to withdraw statin. At baseline and 5 days later, blood samples will be collected for experimental measures.